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A cDNA encoding a novel member of the G-protein-coupled receptor (GCR) superfamily. an ATP receptor, has been isolated from an embryonic 
chtck whole brain cDNA hbrary by hybridizatton screenmg. The encoded protein has a sequence of 362 amino acids (41 kDa) and shares no more 
than 27% amino acid identity with any known GCR. When expressed as a complementary RNA (cRNA) m Xenopus oocytes a slowly-developing 
inward current was observed in response to application of ATP. The pharmacology of this expressed protem defines it as a PZv purinoceptor. 
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1. INTRODUCTION 
Evidence has accrued for many years that ATP can 
act as a neurotransmitter or modulator in both the pe- 
ripheral and the central nervous system [l-3]. The ef- 
fects of extracellular ATP are mediated via specific re- 
ceptors, the P, purinoceptors: which are entirely distinct 
from those that bind adenosine [2]. At least five sub- 
types of P, purinoceptors have been proposed pharma- 
cologically [2,4], with P,, and PzY purinoceptors the 
best described. However, none has as yet been char- 
acterised at the molecular level. The P,, purinoceptor 
has the properties of an ATP-gated cation channel [5], 
whereas other P, purinoceptor subtypes appear to be 
members of the GCR superfamily [4,6]. 
sequence to canine adenosine receptors [lo]. To isolate 
related sequences, we used this clone to screen an em- 
bryonic chick whole brain cDNA library. In this report 
we describe the cloning and expression of a cDNA en- 
coding a novel GCR that binds ATP. This receptor 
displays a P,, purinoceptor pharmacology distinct from 
the classical [2,4] type. On the basis of this pharmacol- 
ogical evidence, we designate this novel subtype as a 
PzY, purinoceptor. This designation is supported by the 
restricted expression of the corresponding mRNA tran- 
script. 
2. MATERIALS AND METHODS 
2 1. Poiwwuse charrz reaction. cDNA library screenmg und DNA se- 
At around the time of hatching, the brain of the chick 
is known to be in a phase of highly active expression of 
many receptor mRNAs, as confirmed in oocyte expres- 
sion studies [7,8]. Investigating sources of ATP recep- 
tors, we found that this brain is, in fact, exceptionally 
rich in high-affinity ATP-binding sites of the Ply sub- 
types (J.S. and T.E.W., unpublished). We have cloned 
a brain partial cDNA [9] that encodes the guinea pig 
equivalent of an unidentified receptor [lo] of the G- 
protein-coupled class, RDCl, which is most related in 
Two degenerate oligonucleotide prrmers. from transmembrane 
domains II and VI of G-protein-coupled receptors. 5’-TAGGTC 
GAC(G/C)(G/C)TGT(G/C)(TIC)CTGGC(C/T)GTGGC(C/T)GC- 
tA/C)T-3’ and 5’-AGGACGAATTCGGG(G/A/C)(GIA)ICCAAGT 
CAG(AIG)AT(GIA)AAG(G/A)C-3’. were used to amplify other 
members of the GCR superfamily from guinea pig brain first-strand 
cDNA. The amplification condrtrons were as follows: 94”C, 1 min. 
55”C, 1 min. 72°C. I min; 30 cycles [9]. Amphfication products were 
subcloned. making use of the restrictton endonuclease sites incor- 
porated into the 5’-ends of each primer, into complementary restricted 
M13mpl8 for sequence analysis (Sanger dideoxy chain termination, 
Sequenase kit. USB) 
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A 497-bp cDNA fragment that encoded part of a RDCl-like se- 
quence [9] was labelled (random primer method) to a specific activity 
of approximately 1 x IO9 dpm/pg and used to screen 5 x lo5 recombi- 
nants of an embryonic chtck whole bram cDNA library (AptlO, gift 
of A. Hrcks [ 111). Hybridisatlon was in 6 x SSC at 65°C for 18 h; the 
final wash condtttons were 1 x SSC at 55°C. Three hybrtdization 
classes of strong to weak intensity were distingmshed DNA from a 
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GAATTCGA~CGCGOCCCCG~AT~~~~~~~G~~C~~CG~C~CT~~~~~G~~ AGCGGAGGAGAGAGCGCGGAGCGGA 
* M 
GCGCCOCGAOGOAOGCAGATGCGTTGCTGTTGCTGTTCCCGTAGAGCCTTCGCCG~TCGTCCCAGOCCGATGTGAGCGCOCCOOGAGOATCATCATGA 
TEALISAA L(N/QPE LLAGGWAAG/%?-?lTT/TC 
CCGAAGCCCTCATCTCTGCTGCTCTGAACGCOACOCAGCCGCT 
I 
S LTKTGFQ F Y Y L P T V Y I L V F I T G F L G N S V A 
CCCTGACCAAAACOGGCTTCCAGTTCTACTACCTGCCCACCGTCTACATCCTCGTCTTCATCACCGGGTTCTTDGGC~CAGCGT~CCA 
II 
I WMFVFHMRPWSGI SVYMFNL ALADFLYVL 
TCTGCATGTTCGTCTTCCACATGCOGCCGTGGAGCDGC~AT~CGGTGTACATGTTCAACCTOCTCTGCCCOACTTCCTTCCTGTATGTCCTCA 
T L P A L I FYYFIKIDWIFGD V M C KLQRFIFH 
CCCTGCCCDCCCTCAT~TCTACTACTTCAAC~ACCGA~~ATCTTC~ACGTCATGTGC~G~GCAGA~TTCATTTTCCA~ 
In 
VNLYGSILFLTCISVH RYTGVVHPLKSLGR 
TGAACCTCTACGGCAGCATCCTGTTCCTCCTCATAAGGTCGTGCACCCGCTGAAGTCGCTGGOGAOGC 
n 
L KKKNAVYVSSL V W A LVVAVIAPILFYSGT 
TG~GAAGAAGAACGCCGTGTACCPCGCTOCTOTTCTACTCAOGCACCC 
GVRR(N/ITCY DTTADEYLRS YFVYSMCTT 
OGOTGAGGAGGAACAAAACCATCACOTGerACGACACCACGOCCGACGAGTAC~GC~AG~ACTTCGTGTACAGCATGT~ACCAC~ 
\ 
VFMFCIPFIVILGCY GLIVKALIYKDLDNS 
TGTTCATGTTCTGCATCCCCTTCATCGTCATCCTCGGCTGCTACGGGCTGATCGTGAAAGCTCTGATCTACAAGGACCTGGACAACTCTC 
m VI 
P LRRKSIYLVIIVLTV F A V S Y L P F H V M K T L 
CTCTOCGOAOGAAGTCCATCTACCTGGTCATCATCGTGTTGACGGTCTTCCCCGTCTCCTACCTCCCCTTCCACGTGATGAAGACCCTGA 
NLRARLDF Q T P Q M C A F PJ D K VY A T Y Q V T R G L 
ACCTGAOGOCCAGGCTOGATTTCCAGACGCCGCAGATGTGTGCCTTCAACGACAAGGTGTACGCCACCTACCAGGTGACCCGGOGG 
VII m q 0 
A S L N S CVDPILY FLAGDTF R R R L S RATRKS 
CCAGCCTCAACAOCTGCGTCGACCCCATCCTCTACTACTTCCGOGCAT 
0 
S R R S E P N V Q S X S E EMTLNILTEYKQ PI G D T S 
CCCGGACDAGCGAGCCCAACGTGCAGTCCAAGAGCGA~AGATGACGCTCAATATTTTGACAGAGTACICAGAACOGGDACACACCAGTT 
L + 
TGTGAAOOOATGCGAAACGTOTGGGAACGGTTCGCAGTCACGCTGCGCCCTGACACTGCCCCACAGCGCCGCAGCGCCGCACAC~GTGTGT~T 
CCTCTGCCCGTCCCCACTCATTTTAGATICAAGGCTTTTTTTTTCTAAGATTACOAAATC 
TTAGCGGAGAATAACATGTCACGAGTTCAGGACTGATCGGTTC 
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Fig. 1. Nucleotide and predicted amino acid sequence (single letter code) of the 803 protein. Putative transmembrane domains as determined by 
the Kyte-Doolittle algorithm [IS] are overlined and numbered. Potential sites for N-linked glycosylation are boxed. Potential sites for phosphoryl- 
ation by protein kinase A and protein kinase C are indicated by solid and open squares, respectively. 
phage of middle intensity, clone 803, was isolated by standard proce- 
dures and the whole EcoRI insert was subcloned to the same site in 
M13mp18 and subjected to sequence analysis. 
2.2. In vitro franscriptlon, oocyte preparation, mrcroinjection and elec- 
trophysiologzcai measurements 
The 1 S-kb cDNA insert from 803, was subcloned into the EcoRI 
site of the expression vector pSG5 (Stratagene). Capped and polyad- 
enylated cRNA was transcribed in vitro from this construct. linearised 
with EarnHI, using a riboprobe kit (Promega). cRNA (- 50 ng in 50 
nl per oocyte) was Injected into oocytes retainmg their follicular enve- 
lope, as previously described [8]. After 2-3 days at 18°C m modified 
Barth’s medium, they were maintained at 4°C for at least 11 days [8]. 
Two-electrode voltage clamping (Axoclamp 2A amplifier) was used at 
room temperature. The voltage-recording and current-injecting elec- 
trodes were filled with 0.6 M K,SO, and 3 M KCl, respectively. 
Oocytes were superfused at a rate of 10 ml/mm (bath volume 0.2 ml) 
with an amphibian Ringer (mM). 110 NaCl, 2 KCl. 5 HEPES, 2 
Fig. 2. Responses in cRNA-injected Xenopus oocytes (at -40 mV). (Aa) Dose-dependence of membrane currents evoked by ATP (lo-300 ,L~MT 
The transient downward deflections morntor the input conductance following hyperpolarizing voltage steps (-10 mV, apphed every 5 s for 1 s). 
Similar results were observed in two other oocytes. (Ab.c) In two oocytes. the agomst selectivity was assessed usmg 2-MeSATP, ATP, ADP. 
a&MeATP and UTP. Holding potentials, -40 mV. (B) ATP concentration-response relationship. The membrane current amplitude (IATp) was 
measured using the initial peak inward current induced by each ATP concentration. (C) Suramin antagonized the responses to (Ca) ATP and (Cb) 
2-MeSATP. RB also inhibited the responses to (Cc) ATP and (Cd) 2-MeSATP. Note, in (A) and (C). the slower chart speed in some records during 
drug washout and the incomplete recoveries following treatment with RB. Bar indicates hgand apphcation. 
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MTEALISAALNGTQPELLAGGWAAGNATI'KCS-LTKTGFQFY-----YLPTV 46 
MDLHLFDYAEPGNFSDISWPCNSSDCIVVDTVLCPNMPNKSVLLY-----TLSFI 50 
MILNSSTEDGIKRIQDDCPKAGAGRHNYIFV-----MIPTL 34 
MGPRRLLLVAACFSLCGPL- (54) -1NKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSV 108 
MELNSSSRVDSEFRY---TLF-PIV 21 
MPPAISAFQAAYIG-I 15 
MSTMGSW--WIT-V 12 
YILVFITGFLGNSVAIWMF-VFHMRPWSGISVYMFNLALAD FLY-VLTLPALIFYYF'NK 103 
YIFIFVIGMIANSVVVWVN-- IQAKTTGYDTHCYILNLAIADLWV-WTIPWWSLVQH 107 
YSIIFVVGIFGNSLWIVI--YFYMKLKTVASVFLLNLALAD LCF-LLTLPLWAVYTAME 91 
YTGVFVVSLPLNIMAIWF--ILKMKVKKPAVVYblLHLATADVLF-VSVLPFKISYYFSG 165 
YSIIFVLGIIANGYVLWVFARLYPSKKLNEIKIFMVNLTVADLLF-LITLPLWIVYYSNQ 80 
~LIALVSVPGNVLVIWAV--KVNQALRDATFCFIVSLAILINIGP 73 
ELAIAVLAILGNVLVCWAV--WLNSNLQNVTNYFWSLAAADIAVGVLAIPFAITISTGF 70 
TDWIFGDVMCKLQRFIFHVNLYGSILFLTCISVHRYTGVVHPLKSLGRLKKKNAVYVSSL 163 
NQWPMGELTCKITHLIFSINLFGSIFFLTCMSVDRYLSIlYFASTSSRRIUCVVRRAVCVL 167 
YRWPFGDSYLCKIASASVSFNLYASVFLLTCLSIDRYLALCII 151 
SDWQFGSELCRFVTAAFYCNMYASILLMI'VISIDRFLA~PMQSLSWRTLGRASFTCLA 225 
GNWFLPKFLCNLAGCLFFINTYCSVAFLGVITYNRFQAVKYPIKTAQATTRKRGIALSLV 140 
RTYFHT---CLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKTWTPRRAAVAIAG 130 
CAACHN---CLFFACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRY~JGLVTGTRAKGIIAV 127 
VWALVVAVIAPILF----YSGTGVRRNK----TIT-CYDTTADEYLRSYFVY-SM'?I'TVF 213 
VWLLAFCVSLPDTY----YLKTVTSASN----NETYCRSFYPEHSVKEWLIISMELVSVVL 219 
IWLLAGLASLPAII----HRFFIE~----NI~~F~ESQN-STLPIGLGLT~IL 202 
I~LAIAGWPLVL----KEQTIQVPGL-~--NI~C~VLNETLLEG~A~FSAFSAV 277 
IWVAIVAAASYFLV----MDSTNWSNKAGSGNITRCFEHYEKGSKPVLII---HICIVL 193 
VWILSFWGLTPLFGWNRLGFXAQRAWAANGSGGEPVIKCEFEKVISMEYMVYFNFFVWVL 190 
CWVLSFAIGLTPMLGWNNCSQPKEGRNYSQGCGEGQVACLFEDWPMNYMVYYNFFAFV'L 187 
M-FCIPFI~LGCYGLIVLIYK----DLDNSPL--YL 263 
G-FAIPFCVIAVFYCLLARAISAS-----SDQEKQSS--R-----KIIFS~FLV~ 266 
G-FLFPFLTILTSYTLIWKALKKA-----YEIQ~JKP--RPJDDIFKII~I~FFFFS~ 254 
F-FFVPLIISTVCNSIIRCLS-S-----SAVANRSK--KS~LFLS~~CI-FIICFG 327 
G-FFIVFLLILFCNLVIIHTLLRQ-----PVKQQRNA?X'VRRRALWMVCI%AV-WICFV 246 
PPLLLMVLIYLEVFYLIRRQLGKKVSAS-SGDPQKY-YGKELKIAKSLALILFLFALSWL 248 
VPLLLMLG~LRIFLAARRQLKQMESQPLPGERARSTLQK~H~KSLAIIVGLFAL~ 247 
PFHVMKTLNLRARLDFQTPQMCAFNDKWATYQVTRGLASLNSCVDPILYFLAGDTFRRR 323 
PYHVVVLLDIFSILHY-IPFTCQLENFLFTALHVTQCLSLVHCCVI'JPVLYSFINRl~-R~ 324 
PHQIFTFLDVLIQLGI-IR-DCRIADIMTAMPITICIAYFFLGKKFKRY 312 
PTNVL----LIAHYSFLSHT--STTEAAYFAYLLCVCVSSISSCIDPLI~ASSECQRY 381 
PHHMVQLPWrLAELGMWPS---SNHQAINDAHQVTLCLLS~~LDPVIYCFLTKKFRKH 303 
PLHILNCITLFCP-- --- --SCRKPSI-L--MYIAIFLTHGNSAMNF'IVYAFRIQKFRVT 298 
PLHIINCFTFFCP-------ECSHAPLWL--MYLTIVLSHTNSWNPFIYAYRIREFR~ 298 
LSRATRKSSRRSEPNVQSKSEEBfTLNILTBYKQNGDTSL 362 
ELMKAFIFKYSAKTGLTKLIDASRVSE-TEYSALEQNAK 362 
FLQ---LLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE 359 
VYSILCCKESSDPSSYNSSGQLSKMDTCSSNLNNSIYKKLLT 425 
LSEKLNIMRSSGKCSRVTTDTGTEMAIPINHTPVNPIKN 342 
FLKIimHFRCQPTPPVDEDPPEEAPHD 326 
FRKIIRSHVLRRREPFKAGGTSARALAAHGSDGEQISLRL~JGHPPG~~GSAPH- (58) 411 
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Fig. 3. Comparison of the chick P zyI purinoceptor with the canine orphan RDCl, human angiotensin II type 1 (ANG II), human thrombm. guinea 
pig platelet activating factor (PAF) and canine adenosine, Al and A2 receptors. Numbers in parentheses indicate the amino acids removed, and 
dashes the gaps inserted, to optimise the alignment using the Clustal program [29] (~1.0). Identical results are indicated in bold type. 
CaCl,, pH 7.4. Resting potentials varied from -23 to -65 mV and 
input resistances from 0.5 to 2 MQ. Iclcc., was activated under voltage 
clamp, using a step-pulse protocol to establish whether antagonists 
interfered with the endogenous calcium-activated chloride channel 
[13] in the oocyte. A command step to -100 mV for 1 s was followed 
by a depolarising command for 4 s to +50 mV to activate Ic,,c~,,. before 
returning to the holding potential of -40 mV. This protocol was 
repeated every 20 s in the absence and presence of the antagonists. The 
measured current relaxation was indeed Ic,cc.r smce when external Ca 
was removed and equimolar BaCl, was applied the current was sub- 
stantially reduced. 
2.3. Hybridization analysrs of chicken RNA 
Total cellular RNA from a variety of one-day-post-hatch chick and 
chicken tissues was prepared by CsCl centrifugatton 1121. Poly(A)‘- 
selected RNA was prepared by oligo(dT) cellulose chromatography. 
RNA was electrophoresed through a 1% formaldehyde 0.8% agarose 
gel. Following electrophoresis, RNA was blotted to Hybond-N nylon 
membrane (Amersham) and hybridisation was performed at 42°C in 
50% formamide [12]. The hybridisation probe was an antisense 45 
base oligonucleotide corresponding to the DNA sequence encoding 
amino acids l-15 of 803 and was labelled by terminal deoxynucleoti- 
dyl transferase to a specific activity of approximately 1 x lo9 dpm/pg. 
The filter was washed at 65°C in 1 x SSC, 0.1% SDS for 15 min before 
being exposed to an X-ray film at -7O‘C with an intensifying screen, 
Exposure: 10 days (1 day for chick brain). 
3. RESULTS AND DISCUSSION 
A guinea pig partial cDNA [9] was used to screen 
5 x lo5 recombinants of an embryonic chick whole 
brain cDNA library. Sequence analysis of one of the 
isolated clones, 803, revealed the presence of an open 
reading frame of 1,068 bp. The predicted amino acid 
sequence and the nucleotide sequence are presented in 
Fig. 1. The putative initiator methionine is in agreement 
with the optimal sequence for translation [14] and the 
presence of an in-frame stop codon upstream of this 
methionine codon indicates that 803 encodes the entire 
coding region of a polypeptide of 362 amino acids with 
a calculated molecular weight of 41 kDa. The hydro- 
phobicity profile [15] (not shown) of the predicted 
amino acid sequence revealed the typical pattern of a 
GCR and exhibited seven hydrophobic domains. The 
sequence possesses other common features [ 161 of the 
GCR superfamily, including: (a) consensus sequences 
for N-linked glycosylation near the amino terminus and 
in the first two extracellular loops; (b) two conserved 
cysteine residues, one in each of the first two extracellu- 
lar loops, that are believed to form a disulphide bond 
which stabilises the functional protein structure; (c) 
serine and threonine residues in the third cytoplasmic 
loop and COOH-terminal domain, which represent po- 
tential phosphorylation sites and may play a role in 
receptor desensitization (Fig. 1). 
To establish the identity of the 803 protein, Xenopus 
Levis oocytes were injected with in vitro transcribed 
cRNA prepared from clone 803 [7,8]. ATP (1 PM-I 
mM) caused a slowly-developing inward current associ- 
ated with a conductance increase, in cRNA-injected 
oocytes (Fig. 2Aa). The slow but large, concentration- 
dependent outward currents and conductance increases, 
which can be seen in non-injected control oocytes, re- 
presenting activation of native adenosine receptors, 
were completely inhibited by bath application of 100 
PM theophylline 1171. Therefore, all experiments were 
performed in the presence of theophylline, which does 
not interfere with responses to Pz receptor activation 
[17]. After inhibition with theophylline, reapplication of 
100 PM ATP did not reveal any previously occluded 
oscillatory inward current in control oocytes. Mem- 
brane current and conductance oscillated during and 
for some time after agonist application. The observed 
responses, together with a reversal potential of -24 mV, 
indicated the involvement of a Ca-activated Cl- current 
(ZcICC,,) [13] which is normally evoked in the oocyte by 
expressed GCRs [18]. Responses to ATP were dose- 
dependent, with a threshold concentration of approxi- 
mately 10 PM and an EC,, (half-maximal concentra- 
tion) of 49.5 +_ 6 PM (Fig. 2Aa.2B). Repeated applica- 
tions of the same concentration of ATP produced con- 
sistent responses, with a negligible decline in response 
amplitude over time. Inward currents were also induced 
by 2-methylthio-ATP (2-MeSATP) and ADP. In con- 
trast, UTP and the P,,-selective agonists [2] a$-meth- 
ylene-ATP (a,/?-MeATP), and P,y-methylene-ATP 
(P,y-MeATP) were inactive at concentrations up to 30- 
100pM (Fig. 2A). The relative order of agonist potency 
(as judged by matched-response amplitudes) was: 2- 
MeSATP 2 ATP > ADP >> a&MeATP, P,y-MeATP, 
UTP. This specificity was found likewise in radioligand 
binding studies performed on chick brain membranes, 
or on 803 transfected cos-7 cells, with a high-affinity 
binding site for ATP being present (to be reported else- 
where). In injected oocytes both suramin (100 PM) and 
the P,,-selective antagonist [19] Reactive Blue 2 (RB) 
(10 PM) antagonised the responses to ATP and to 2- 
MeSATP (Fig. 2Ca,Cb) without appreciably affecting 
native Zc,(ca). The high potency of ATP and the inactiv- 
ity of the methylene ATPs and of UTP identified this 
receptor as a Pzu subtype rather than a Pzx or P,, sub- 
type. The near equipotency of 2-MeSATP and ATP, 
and greater potency of ATP over ADP, suggested that 
this expressed receptor is a novel subtype of the P, 
purinoceptor family. We have therefore designated this 
receptor as PzY,. 
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Fig. 4. Tissue distribution of the transcript corresponding to the PZv, receptor. A Northern blot of chick (one-day-post-hatch) whole brain poly(A)’ 
(10 p(g) and total RNA (30 pug) from various chick and adult tissues was subjected to Northern analysis as described in Section 2. Tissues were: 
Bc, chick brain; Hc. chick heart; Lc, chick liver; and from adult chicken. B, brain; H. heart; L, liver: G. gastrointestinal tract; ST, stomach; SP, 
spleen; K, kidney; SC. spmal cord: LU, lung; LM, leg muscle. Band size (arrow) was determined using RNA standards (BRL). Bands were absent 
from the regions of the blot not shown 
Comparison of the P,,, purinoceptor with other chicken: it was present in brain, spinal cord, gastrointes- 
cloned GCR sequences places it in the major family of tinal tract, spleen and leg muscle (Fig. 4) but was not 
these receptors [20]: negligible sequence identity was detected in heart, liver, stomach, lung or kidney. The 
seen with either the secretinlcalcitonin or the glutamate transcript was also found in the brain of newly-hatched 
receptor gene families. P,,, shares no more than 27% chick (Fig. 4). Pzu purinoceptors are abundant in the 
identity with known GCR sequences (Table I), suggest- mammalian gastrointestinal tract and spinal cord [2] 
ing that this receptor protein is in a previously unknown but their distribution in chicken tissues is unknown. 
subdivision of this major receptor family. It is of interest However, in developing chick skeletal muscle P2 purino- 
that the P,,, receptor has only a low sequence identity ceptors have been found in physiological studies, but 
with the adenosine [lo] (21%) and CAMP [21] (17%) not of the defined PLY type [24]. The existence of Pzu 
receptors (Table I, Fig. 3). The PzY, receptor sequence purinoceptors in mammalian liver, kidney. pancreas, 
does not contain ATP binding motifs [22] of the type blood vessels and heart has also been reported [2,25- 
G[X],GK. The absence of a linear ATP binding motif 271, but the observed pharmacology of these receptors 
is not surprising, since it is likely that the ligand-binding differ [5] from the purinoceptor described here. Our 
pocket for a molecule the size of ATP will be formed by data support the hypothesis that the chick Pzv, purino- 
residues in several transmembrane domains as in the ceptor is distinct from the P,, purinoceptors described 
case of the catecholamine receptors [23]. previously in visceral tissues. 
The tissue distribution of the P,,, transcript was de- 
termined by Northern hybridisation. The mRNA (3.1- 
kb) had a discrete pattern of expression in the adult 
Table I 
Percentage identity of chick PZY, purinoceptor with known G-protein- 
coupled receptors 
Receptor Species % Identity 
with PZv, 
ATP is known to act as a fast neurotransmitter in 
peripheral and central neurones, via P,, purinoceptor 
cation channels [5.28]. The presence of Pzvl purinocep- 
tors in the brain indicates the involvement of ATP in 
metabotropic, slow synaptic transmission. Indeed, the 
high concentration of the Pzv, mRNA and the exceed- 
ingly high and specific binding capacity for ATP in the 
developing chick brain (J.S. and T.E.W.. unpublished) 
is indicative of a more significant role for a PzY purino- 
ceptor in the brain than has hitherto been suspected. 
RDCI 
Angiotensin II type 1 
Thrombin 
Platelet activating factor 
C5a anaphylatoxin 
Neuromedm K 
Interleukin 8 
Bradykinm B2 
Neurotensin 
Endothelin B 
Gastrin-releasing peptide 
Adenosine Al 
Substance P 
Neurokinin 2 
Adenosme A2 
CAMP 
canine 27 
human 27 
human 25 
guinea pig 25 
human 23 
rat 23 
human 22 
rat 22 
rat 21 
human 21 
mouse 21 
canine 21 
human 20 
human 20 
canme 18 
slime mold 17 
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